Additionally, the use of the human epidermal growth factor 2 (HER2)-directed antibody–drug conjugate Trastuzumab deruxtecan has shown efficacy in pre-treated patients with HER-2 expressing tumors, including cervical cancer [24]. Here, ERBB2 is linked to cervical carcinoma.